3
Clinical Trials associated with Canakinumab Biosimilar (Mabpharm)A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2357
An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305; and response characterisation study in canakinumab treatment-naive patients with active SIJA with and without fever(Cohort 2 (treatment naive patients) only applicable in countries where approved) - G2301E1
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy - H2251
100 Clinical Results associated with Canakinumab Biosimilar (Mabpharm)
100 Translational Medicine associated with Canakinumab Biosimilar (Mabpharm)
100 Patents (Medical) associated with Canakinumab Biosimilar (Mabpharm)
100 Deals associated with Canakinumab Biosimilar (Mabpharm)